Rocket Gets FDA Nod To Advance RP-A501 Phase 2 Trial In Danon Disease; Stock Up

Rocket Pharmaceuticals announced alignment with the U.S. FDA to continue patient enrollment and dosing and on key elements of a pivotal Phase 2 trial. The regulatory clarity is a constructive development for the company’s genetic-medicine program targeting rare, life-threatening diseases, though the article excerpt provides no clinical efficacy or safety data.